Artiva Biotherapeutics, Inc. (ARTV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Artiva Biotherapeutics, Inc. in 2026. The next earnings report is expected on August 27, 2026.
Artiva Biotherapeutics, Inc. missed consensus estimates in its latest earnings report, with a loss per share of $0.63 versus an estimated loss of $0.6251 and revenue of $0 meeting forecasts. In the prior quarter, EPS also missed expectations while revenue again met estimates.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.